125 related articles for article (PubMed ID: 37643244)
21. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
22. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
23. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
[TBL] [Abstract][Full Text] [Related]
24. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
25. Lipids and the cancer stemness regulatory system in acute myeloid leukemia.
Lim INX; Nagree MS; Xie SZ
Essays Biochem; 2022 Sep; 66(4):333-344. PubMed ID: 35996953
[TBL] [Abstract][Full Text] [Related]
26. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
[TBL] [Abstract][Full Text] [Related]
27. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-33/ST2 Signaling Promotes Hepatocellular Carcinoma Cell Stemness Expansion Through Activating c-Jun N-terminal Kinase Pathway.
Zhao R; Yu Z; Li M; Zhou Y
Am J Med Sci; 2019 Oct; 358(4):279-288. PubMed ID: 31420092
[TBL] [Abstract][Full Text] [Related]
29. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia.
Vuelta E; Ordoñez JL; Alonso-Pérez V; Méndez L; Hernández-Carabias P; Saldaña R; Sevilla J; Sebastián E; Muntión S; Sánchez-Guijo F; Hernández-Rivas JM; García-Tuñón I; Sánchez-Martín M
CRISPR J; 2021 Aug; 4(4):519-535. PubMed ID: 34406033
[TBL] [Abstract][Full Text] [Related]
30. BCR/ABL can promote CD19
Li D; Zhao X; Zhang R; Jiao B; Liu P; Ren R
Stem Cell Investig; 2016; 3():85. PubMed ID: 28066787
[TBL] [Abstract][Full Text] [Related]
31. Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia.
Muselli F; Mourgues L; Rochet N; Nebout M; Guerci A; Verhoeyen E; Krug A; Legros L; Peyron JF; Mary D
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765952
[TBL] [Abstract][Full Text] [Related]
32. Deregulated Notch and Wnt signaling activates early-stage myeloid regeneration pathways in leukemia.
Kang YA; Pietras EM; Passegué E
J Exp Med; 2020 Mar; 217(3):. PubMed ID: 31886826
[TBL] [Abstract][Full Text] [Related]
33. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
[TBL] [Abstract][Full Text] [Related]
34. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
[TBL] [Abstract][Full Text] [Related]
35. Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling.
Li Y; Hu J; Song H; Wu T
Biochem Biophys Res Commun; 2018 Nov; 505(3):858-864. PubMed ID: 30301525
[TBL] [Abstract][Full Text] [Related]
36. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
38. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia.
Ito K; Ito K
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830976
[TBL] [Abstract][Full Text] [Related]
39. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
[TBL] [Abstract][Full Text] [Related]
40. Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells.
Charaf L; Mahon FX; Lamrissi-Garcia I; Moranvillier I; Beliveau F; Cardinaud B; Dabernat S; de Verneuil H; Moreau-Gaudry F; Bedel A
Leukemia; 2017 Jan; 31(1):65-74. PubMed ID: 27220663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
